Arcutis Biotherapeutics Inc (ARQT) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

Total Assets Chart for Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc (ARQT) total assets for FY2025 were USD 433.0M, a 24.1% change from FY2024. Arcutis Biotherapeutics Inc's total assets grew from USD 3.8M in 2017 to USD 433.0M in 2025 (11237.3% over 8 years). Total assets compound annual growth rate: 5-year CAGR of 7.7%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$3.92B
Implied Share Price
$31.20
Enterprise Value
$2.47B
Revenue (TTM)
$463.98M
EBITDA
$36.50M
Profit Margin
6.15%
Trailing P/E
141.82
Forward P/E
263.16
Price/Book (MRQ)
18.33
Price/Sales (TTM)
8.45
EV/EBITDA
-2.04
EV/Revenue
9.36
Dividend Yield
—
Book Value
$1.76
Free Cash Flow (FY2025)
-$6.31M
Free Cash Flow Yield
-0.16%

Snapshot as of 25th October 2026 — not point-in-time controlled, may lag the live market by a few days.